| abstract |
The present invention relates to novel heterocyclic compounds of formula (I) based on quinazoline scaffolds, which bind efficiently to mitochondrial translocation proteins (TSPO) and resist cell death processes. These compounds can also stimulate neuronal differentiation. The present invention further relates to pharmaceutical compositions comprising such compounds, and methods of using these compounds to prevent and treat brain injury caused by brain injury, particularly secondary brain injury due to traumatic brain injury (TBI). The compounds of the present invention are also useful in the prevention, treatment and cure of brain damage due to neurodegenerative diseases, including underlying and associated pathological and psychiatric disorders. The compounds can also be used to prevent and treat brain damage due to infections, intoxication attacks, and overdose of drugs such as recreational, over-the-counter, or prescription drugs. These compounds can also prevent, for example, heart failure associated with brain injury and brain disease. |